$0.94
+0.08 (+9.38%)
Open$0.88
Previous Close$0.86
Day High$0.95
Day Low$0.86
52W High$2.50
52W Low$0.50
Volume—
Avg Volume50.3K
Market Cap37.54M
P/E Ratio0.75
EPS$1.16
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,076.4% upside
Current
$0.94
$0.94
Target
$11.07
$11.07
$6.75
$11.07 avg
$12.78
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 11.84M | 18.80M | 7.77M |
| Net Income | 51.41M | 73.46M | 1.80M |
| Profit Margin | 434.2% | 412.5% | 23.2% |
| EBITDA | -23,236,371 | -35,044,534 | 2.38M |
| Free Cash Flow | — | — | 1.78M |
| Rev Growth | -37.0% | -37.0% | +3.8% |
| Debt/Equity | — | — | 0.84 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |